clinical trial of halozyme’s PEGPH20 in combination with modified folfirinox for advanced pancreatic cancer. The company announced that the U.S. Food and Drug Administration or FDA has removed the clinical hold on patient enrollment and dosing of PEGPH20 in SWOG’s ongoing Phase 1b/2 clinical trial (S1313). Halozyme Therapeutics, Inc. (NASDAQ:HALO) belongs to Healthcare sector. Its weekly performance is -1.73%. On last trading day company shares … Continue reading Investors Watch List : Halozyme Therapeutics, Inc. (NASDAQ:HALO), Yahoo! Inc. (NASDAQ:YHOO), Otter Tail Corporation (NASDAQ:OTTR), Omnicare Inc. (NYSE:OCR), International Business Machines Corporation (NYSE:IBM),